Matthew Scott Harris M.D., MS, FCAP, AGAF
Net Worth

Last updated:

What is Matthew Scott Harris M.D., MS, FCAP, AGAF net worth?

The estimated net worth of Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF is at least $3,271,700 as of 2 Feb 2024. He owns shares worth $119,920 as insider, has earned $265,830 from insider trading and has received compensation worth at least $2,885,950 in Altimmune, Inc..

What is the salary of Matthew Scott Harris M.D., MS, FCAP, AGAF?

Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF salary is $577,190 per year as Chief Medical Officer in Altimmune, Inc..

How old is Matthew Scott Harris M.D., MS, FCAP, AGAF?

Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF is 72 years old, born in 1953.

What stocks does Matthew Scott Harris M.D., MS, FCAP, AGAF currently own?

As insider, Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF owns shares in one company:

Company Title Shares Price per share Total value
Altimmune, Inc. (ALT) Chief Medical Officer 33,311 $3.6 $119,920

What does Altimmune, Inc. do?

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT logo
ALT
Altimmune, Inc.
$3.6

Matthew Scott Harris M.D., MS, FCAP, AGAF insider trading

Altimmune, Inc.

Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF has made 2 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 30,000 units of ALT stock on 28 Feb 2022. As of 2 Feb 2024 he still owns at least 33,311 units of ALT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock, par value $0.0001 7,775 N/A N/A
Option
Restricted Stock Units 7,775 N/A N/A
Option
Restricted Stock Units 6,166 N/A N/A
Option
Common Stock, par value $0.0001 6,166 N/A N/A
Option
Restricted Stock Units 9,275 N/A N/A
Option
Common Stock, par value $0.0001 9,275 N/A N/A
Purchase
Common Stock, par value $0.0001 10,000 $4.22 $42,200
Option
Common Stock, par value $0.0001 7,775 N/A N/A
Option
Restricted Stock Units 7,775 N/A N/A
Option
Common Stock, par value $0.0001 6,166 N/A N/A
Option
Restricted Stock Units 6,166 N/A N/A
Sale
Common Stock, par value $0.0001 30,000 $7.52 $225,600
Option
Stock Options (option to buy) 30,000 $1.92 $57,630
Option
Common Stock, par value $0.0001 30,000 $1.92 $57,630
Option
Restricted Stock Units 6,166 N/A N/A
Option
Common Stock, par value $0.0001 6,166 N/A N/A
Sale
Common Stock, par value $0.0001 4,015 $10.02 $40,230

Altimmune key executives

Altimmune, Inc. executives and other stock owners filed with the SEC: